High Density Lipoprotein Complexes as Delivery Vehicles for Breast Cancer Chemotherapy

2002 ◽  
Author(s):  
Andras G. Lacko
Keyword(s):  
Breast Cancer ◽  
High Density Lipoprotein ◽  
Cancer Chemotherapy ◽  
Density Lipoprotein ◽  
High Density ◽  
Breast Cancer Chemotherapy ◽  
Delivery Vehicles

P056 High-density lipoprotein (HDL) subfractions and progesterone receptor in breast cancer patients

The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S46
Author(s):  
V.G. Flote ◽  
R. Vettukattil ◽  
T. Egeland ◽  
A. Mctiernan ◽  
H. Frydenberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
High Density Lipoprotein ◽  
Cancer Patients ◽  
Density Lipoprotein ◽  
High Density ◽  
Breast Cancer Patients ◽  
Hdl Subfractions

scholarly journals Characterization of high density lipoprotein from egg yolk and its ability to form nanocomplexes with chitosan as natural delivery vehicles

2018 ◽  
Vol 77 ◽  
pp. 204-211 ◽  
Author(s):  
Mingyong Zhou ◽  
Qiaobin Hu ◽  
Taoran Wang ◽  
Jingyi Xue ◽  
Yangchao Luo
Keyword(s):  
High Density Lipoprotein ◽  
Density Lipoprotein ◽  
Egg Yolk ◽  
High Density ◽  
Delivery Vehicles

Decreased Serum HDL at Initial Diagnosis Correlates with Worse Outcomes for Triple-Negative Breast Cancer but Not Non-TNBCs

2015 ◽  
Vol 30 (2) ◽  
pp. 200-207 ◽  
Author(s):  
Ying Fan ◽  
Xiaoyan Ding ◽  
Jiayu Wang ◽  
Fei Ma ◽  
Peng Yuan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Density Lipoprotein ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Elevated Serum ◽  
Density Lipoprotein ◽  
Serum Glucose ◽  
High Density ◽  
Initial Diagnosis ◽  
Low Hdl

Purpose This study aimed to evaluate the associations between metabolic syndrome (MS) and its components at initial diagnosis and outcomes of breast cancer including triple-negative breast cancer (TNBC) and non-TNBC. Methods A cohort of 1,391 patients was reviewed between January 2004 and July 2008 (including 394 TNBC and 855 non-TNBC cases). MS and its components including body mass index (BMI), serum high-density lipoprotein (HDL) and triglycerides (TG) and their relationships with clinical outcomes were analyzed and then compared between groups. Results The incidences of MS and its components including BMI, the levels of HDL and TG were not differently distributed between the 2 groups (all p's >0.05). However, more TNBC than non-TNBC patients presented with hypertension and elevated serum glucose (20.3% vs. 14.9% and 16.0% vs. 10.8%, p = 0.018 and p = 0.012, respectively). TNBC patients had poorer 5-year relapse-free survival (RFS) than non-TNBC patients (72.8% vs. 84.2%, p<0.0001). Only in the TNBC group, patients with low high-density lipoprotein (HDL) demonstrated worse RFS and overall survival (OS; p<0.0001). Multivariate analysis identified that low HDL was an independent worse prognostic factor for both RFS (hazard ratio [HR] = 3.266, 95% confidence interval [95%CI], 2.087-5.112, p<0.0001) and OS (HR = 3.071, 95%CI, 1.732-5.445, p<0.0001) in TNBC patients. Conclusions Decreased level of HDL may predict worse outcomes both in terms of RFS and OS for TNBC patients but not for non-TNBC patients. Further investigations are warranted to detect the underlying mechanisms.

scholarly journals Differential expression of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
High Density Lipoprotein ◽  
Differential Expression ◽  
Binding Protein ◽  
Density Lipoprotein ◽  
Normal Breast ◽  
High Density ◽  
Differentially Expressed ◽  
Primary Tumors ◽  
Lipoprotein Binding

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1, GPIHB1, when comparing primary tumors of the breast to the tissue of origin, the normal breast. GPIHB1 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of GPIHB1 in primary tumors of the breast was correlated with distant metastasis-free survival in patients with luminal B subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. GPIHB1 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

Sign in / Sign up

Export Citation Format

Share Document